Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormonesensitive prostate cancer (mHSPC): A public payer perspective using network metaanalysis

被引：0
|
作者：
Kohli, Manish
Dougherty, Maura
Cutshall, Zachary
Beckstead, Rylee
Kohli, Rhea
Haaland, Benjamin
Nelson, Richard
Yoo, Minkyoung
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5081
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
    Goudarzi, Zahra
    Lotfi, Farhad
    Najafpour, Zhila
    Hafezi, Aliakbar
    Zakaria, Marzieh Alizadeh
    Keshavarz, Khosro
    BMC UROLOGY, 2024, 24 (01)
  • [32] Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
    Zahra Goudarzi
    Farhad Lotfi
    Zhila Najafpour
    AliAkbar Hafezi
    Marzieh Alizadeh Zakaria
    Khosro Keshavarz
    BMC Urology, 24
  • [33] Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [34] Cost-effectiveness analysis of metformin with enzalutamide in the metastatic castrate-resistant prostate cancer setting
    Hill, Jordan
    Paulden, Mike
    McCabe, Christopher
    North, Scott A.
    Venner, Peter
    Usmani, Nawaid
    CANADIAN JOURNAL OF UROLOGY, 2019, 26 (06) : 10045 - 10053
  • [35] COST-EFFECTIVENESS ANALYSIS OF OLAPARIB AND NOVEL HORMONAL THERAPIES IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
    Ko, G.
    Hansen, R.
    VALUE IN HEALTH, 2021, 24 : S52 - S52
  • [36] KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
    Blank, Patricia R.
    Moch, Holger
    Szucs, Thomas D.
    Schwenkglenks, Matthias
    CLINICAL CANCER RESEARCH, 2011, 17 (19) : 6338 - 6346
  • [37] Cost-Effectiveness Analysis of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer From the Brazilian Public System Perspective
    Faria, Eliney Ferreira
    Rosim, Ricardo Papaleo
    Nogueira, Ernesto de Matos
    Tobias-Machado, Marcos
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 29 : 60 - 65
  • [38] Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer
    Romeo, M.
    Soler, G.
    Martinez Villacampa, M.
    Laquente, B.
    Lopez Doriga, A.
    Pisa, A.
    Rey, M.
    Santos, C.
    Salazar, R.
    Germa Lluch, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market
    Davari, Majid
    Ashrafi, Farzaneh
    Maracy, Mohammadreza
    Aslani, Abolfazl
    Tabatabaei, Mohammadreza
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2015, 6
  • [40] Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis
    Norum, J.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 532 - 537
12345